Statins, which include any drug name with a suffix -statin, are a class of medications commonly prescribed to treat high lipids, or cholesterol, with the intention of lowering risks of cardiovascular disease. They are also important to stabilize stents placed for heart blockages, and to help prevent recurrent stroke phenomena. Statins block an enzyme, mercifully abbreviated HMG-CoA reductase, which limits the amount of cholesterol made in the liver. However, side effects include liver damage, muscle and tendon toxicity, and cataract formation with long-term use. Newer evidence (1,2,3) shows statins adversely hurt regenerative cell function. Put another way, the body’s ability to develop new cartilage and bone is hindered with statin use.

Regenerative cells have been used to reduce inflammation and promote cartilage growth in arthritic joints. But when regenerative cells are injected in an orthopedic procedure while on statins, their efficacy is adversely affected. In fact, the effects by statins on regenerative cells is so strong that statins have shown promise in cancer treatment by reducing tumor growth by 80% (3,4) ! Although positive for the field of oncology, statin use is not desirable when applied to orthopedics, where their use can reduce or eliminate any constructive effect a regenerative cell injection would have on conditions such as arthritis.

Patients who are considering regenerative cell injections should discuss with their cardiologist or prescribing physician whether the option of stopping statins is safe for them, and special caution is needed if prior vascular stents or stroke history is present.

References:

1. Mohammadi,M, et al: Clinical use of statins in hematopoetic regenerative cell transplantation: Old drugs and new horizons. Intl J Hematol Oncol Regenerative Cell Res. 2016; 10 (1): 42-50.
2. Izadpanah, R, et al: The impact of statins on biological characteristics of regenerative cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects. Am J Physiol, Cell Physiol. 2015; 309 (8): C 522-31.
3. Renno, AL, et al: Decreased expression of regenerative cells markers by simvastatin in 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer. Toxicol Pathol. 2015; 43 (3): 400-10.
4. Liu,S, et al: Simvastatin suppresses brest cancer proliferation induced by senescent cells. Sci Rep. 2015; 5: 17895.

mm
Subscribe To Updates

Subscribe To Updates

Join Dr. Urse's mailing list to receive the latest news and information about regenerative cell and platelet rich plasma treatments. 

You have Successfully Subscribed!

Pin It on Pinterest

Share This